


# Cortellis Competitive Intelligence™

## 操作指南

Cortellis Competitive Intelligence™ 是全球醫藥情報的綜合資料庫，以創新藥為中心提供藥物研發、臨床試驗、註冊法規、上市銷售及交易等綜合情報。透過 Cortellis™ 平台，您可以獲取藥物研發產品線、交易、專利、公司及行業競爭情報的龐大資料庫資源，並且每日更新。借助這一資源，可繪製不同適應症、作用機制、技術類型藥物及公司競爭格局的全貌；還可獲取藥物及產品線的精準信息，加速決策。


### A · 登入頁面

- 進入 Cortellis™ 平台登入頁面 (<https://www.cortellis.com/intelligence>)，輸入用戶名稱(email)及密碼。





- 如果您忘記密碼，請點擊“Forgotten password?”，並在頁面中輸入您註冊帳號時使用的 email，系統將密碼重設郵件至相應 email，依照郵件中說明即可完成密碼重置。
- 若您有登入問題，請直接聯繫客戶服務：0080-149-1138 工作日 9:00-17:00 或 Email 至 [ts.support.asia@clarivate.com](mailto:ts.support.asia@clarivate.com)。

## B · 登入後顯示 HOME 頁面



- 頁面右上角的用戶名處有下拉選項，其中包括了當前用戶的帳戶概況或設定、提醒(Alert)、檢索歷史和保存的報告，用戶可根據自己的需求保存或刪除相應報告。為保證下次正常登入，每次資料庫使用完畢請登出 (Sign out)。



- 如您需要查看用戶使用指南（英文）、資料庫更新說明、名詞解釋（Training resources）和常見問題與解答，可點選首頁右下角的  查看相應內容。

All ▾

Search Cortellis

Index 🔍

Full Text 🔍

Advanced search | Structure search

Competitive Intelligence

Drugs

Literature

Patents

Patent gazette

View All

Drugs

Companies

Patents

Literature

Drugs

From 31/05/2020 To 07/06/2020

Status Launched ▾

View All 10 Launched Drug

imipenem + relebactam + cilastatin

ixekizumab

ripretinib

enoxaparin

Active drugs coverage by highest status

Discovery

Precinical

Clinical

Approved

Analysis

[Competitive landscape viewer](#) | [Cortellis Analytics - Drug Attrition Rates](#) | [Competitive intelligence matrix](#) | [Virtual merger](#) | [Intellectual property landscape](#)

Launch the competitive landscape viewer to monitor a portfolio via a one click visualization tool, bringing the power of all Cortellis competitive intelligence content into a series of interactive dashboards.

Competitive landscape viewer ?

Resources & updates

Product updates

Upcoming live training

Training resources

Industry insights

Contact us

Feedback

## C · Cortellis Competitive Intelligence™基本功能介紹

- 1

 為常用檢索區，提供快速檢索、進階檢索和化學結構式檢索三種檢索方式，滿足不同檢索需求。
- 快速檢索可在檢索欄中
 

Competitive Intelligence ▾

Search Cortellis

Q

 輸入關鍵詞進行檢索，檢索詞包括：藥物名稱、研究代碼、治療領域或適應症名稱、作用機制、靶點或靶點家族名稱、公司名稱、國家、專利號等，檢索結果會把包含檢索詞的相關結果列出。
  - 根據想要獲取檢索結果範圍的不同，可以選擇進行
 


Full Text 🔍

全文檢索或

 索引檢索。
 

Index 🔍


索引檢索。
  - 檢索支持運算符 AND、OR、NOT，通用符號 \*，精確檢索雙引號 “ ”，優先檢索 ( ) 的使用。可以靈活匹配檢索式（提示：所有的運算符要用英文輸入法）。
  - 索引詞提示，輸入檢索詞時自動顯示提示表單。推薦使用提示表單的檢索詞，這些是經過標準化的檢索詞，可以讓檢索結果更全面準確。



進階檢索提供詳細的檢索條件分類，按您的需求快速獲取相關內容。點擊

[Advanced search](#)

進入進階檢索頁面，選擇不同檢索項進行可組合多條件檢索。



[Drugs](#)

- 可以按照如下條件檢索藥物：在研公司、停研公司、原研公司、在研適應症、停研適應症、作用機制、技術類型、EphMRA 代碼、藥物名稱、最高研發階段、終止時最高研發階段、首次上市狀態、特殊審批資格、藥物記錄添加日期、當前研發狀態、研發概況等。

[Patents](#)

- 可以按照如下條件檢索專利：公司、藥物、適應症、作用機制、技術類型、專利類型、摘要分類、人工代碼、公開國家、標題、摘要、權利要求、預計到期日期、最新變更日期、資料庫記錄添加日期、公開日期、優先權日期、首個優先權日期、首個公開日期等。

[Literature](#)

- 可以按照如下條件檢索文獻：書目信息（標題、作者、出版物、出版時間、資料庫記錄添加時間、機構、地點、摘要等），標準化分類索引（關鍵詞、藥物名稱、研發概況、生物學活性、疾病、代謝、不良反應、作用機制等）

[Clinical Trials](#)

- 可以按照如下條件檢索臨床試驗：臨床試驗標題、識別碼、適應症、患者分層索引、臨床研究階段、臨床試驗中心名稱、臨床試驗開展區域、臨床試驗開展國家或地區、臨床試驗開展州/省/縣、臨床試驗開展城市、

臨床試驗招募狀態、研究者類型、申辦者、合作者、臨床試驗設計、結果、類別、干預措施、生物標記、試驗藥物作用機制/分類/技術類型、試驗終點、不良事件、納入與排除標準、註冊機構聯繫方式、開始時間、結束時間、招募結束時間等。

Regulatory


○ 可以按照標題、摘要、內容、IDRAC 號、來源、國家/地區、語種、文檔類型、產品類別、文件類別、醫療器材分類、法規版本、文件格式、有效狀態、日期等檢索監管文件。

Deals

○ 可以按照如下條件檢索交易：交易標題/概要、公司、交易類型、藥物研發階段、特殊審評、交易財務條款、交易涉及區域、藥物、適應症及治療領域、作用機制、交易開始時間等。

- 結構式檢索：


- 點擊 [Structure search](#) 進入結構式檢索。點擊左側白色面板打開畫圖程序，畫出想要檢索的結構式後點擊 [Transfer](#) 將結構式再轉 [Substructure](#) 移到白板上，選擇完全相同 [Exact match](#) 彈性比對 [Flexible](#) 設定相似度 [Similarity](#) 或子結構進行檢索。




- 畫好的結構式可以透過點擊 [Save mol file](#) 進行保存，也可以透過點擊 [Open mol file](#) 打開一個已保存的 MOL 結構式文件進行檢索。

2


- 為快訊區，從藥物、文獻和專利等不同方向提供最近一段時間發生的變化。
- 在快訊區點擊 [Drugs](#) 可獲得最近一段時間藥物研發階段變更的藥物清單，如上市、核准、臨床 III 期、停研等。



- 點擊 [Literature](#) 獲得最近一段時間不同治療領域相關藥物的文獻情況，如抗生素、腫瘤、心血管等方向最新出版文獻，並可獲得相關文獻的摘要、概述和涉及的藥物信息。




- 點擊 [Patents](#) 獲得最近一段時間不同治療領域相關藥物的專利訊息。



- 點擊 [Patent gazette](#) 可獲得不同專利類型、不同國家/地區的最新藥物專利訊息。





- 3 為功能檢索區，可以透過藥物、公司、專利、文獻進入檢索頁面，獲取相關內容。

Drugs ○ 點擊進入藥物檢索頁面，根據藥物關鍵詞檢索相關藥物內容，並可依需求透過左側 Filters 篩選標籤或者標題欄裡進行內容篩選。  
(同理，點擊 Companies Patents Literature 可分別進入對應檢索頁面，獲取相應內容。)

77154 Drug results

Report Type: Show selected only

Results: 10 Per page: 10 Sort by: Last Change Date Oldest

Drug Name	Originator Company	Active Companies	Therapy Area	Active Indications	Target-based Actions
MGD-013	MacroGenics Inc	MacroGenics Inc; Zai Lab Limited	Cancer	Advanced solid tumor; Cholangiocarcinoma; Hematological neoplasms; Hepatocellular carcinoma; Metastatic liver cancer; Metastatic stomach cancer	CD223 antagonist; Programmed cell death protein 1 inhibitor
remdesivir	Gilead Sciences Inc	Gilead Sciences Inc	Infection	Coronavirus infection; Ebola virus infection; Nipah virus infection	RNA polymerase modulator
CPI-018	Corvus Pharmaceuticals Inc	Corvus Pharmaceuticals Inc	Cancer	Cancer; T-cell lymphoma	Itk tyrosine kinase inhibitor

- 4 為目前資料庫狀態區，即時更新資料庫中藥物所處的研發階段，包括發現、臨床前研究、臨床研究和核准四個狀態。
- 5 為分析工具區，包括競爭格局概覽（Competitive Landscape Viewer，CLV）、新藥研發損耗率分析（Cortellis Analytics-Drug Attrition Rates）、競爭情報分析（Competitive intelligence matrix）、公司虛擬合並與產品線比較（Virtual merger）、專利全景分析（Intellectual property landscape）五個分析工具。
- 點擊 Competitive landscape viewer 進入 CLV，從適應症、作用機制、技術類型和研發公司四個方向檢索，獲得藥物全球研發格局概覽，透過圖表形式呈現藥物產品線的研發階段、研發公司、作用機制、技術類型、藥物研發分布的國家/地區、藥品銷售額及預測、交易、臨床試驗及專利等情況，透

過點擊 **Filters** 每個圖表中的進行篩選篩選、獲取目標內容，點擊每個圖片  
 右上角的 **...** 可放大或下載當前圖片，還可透過點擊頁面中 **Download** 的  
 下載 PPT 或 PDF 格式的競爭格局概覽報告，或點擊 **Save** 保存 CLV 檢索  
 結果、每次進入 CLV 即可自動顯示保存結果。




## D · 檢索結果頁面


- 例如：某公司想查看全球糖尿病產品線、公司、專利、交易等綜合情報，則可以在快速檢索欄 **1** 輸入“diabetes mellitus”。檢索結果頁面如下圖所示。
- 檢索結果顯示共 3183 個藥物符合檢索條件，在 **2** 處還可選擇與檢索結果相關的券商報告、公司、會議、交易、藥物、電話會議逐字稿、文獻、專利、新聞報導、風險投資等進行查看。
- 3** 處可以輸入關鍵詞在檢索結果中進行二次檢索。



- 4 處可以調整每頁顯示檢索結果數；可按照相關性、更新日期、最高研發階段、藥物名稱、銷售額和記錄添加日期進行排序；點擊 [Order Columns](#) 可改變藥物列表中藥物名稱、作用機制、公司名稱、結構式、銷售額等的前後順序。



- 6 處點擊 [Related Content](#) 可連接到藥物列表相關的臨床試驗、交易和公司，點擊 [Analyze](#) 可對檢索結果進行簡單競爭情報分析，點擊 [Save and Alert](#) 可對檢索結果及報告進行保存或設置定時提醒是否有更新，點擊 [Download](#) 下載檢索列表或目標報告（具體操作頁面見下圖說明）。
- 5 選擇不同的瀏覽方式，可按照表格 列表 當前研發階段 和簡單排序 (Ranking) 形式顯示結果，點擊 簡單排序還可對檢索結果中涉及的靶點、公司、最高研發階段等進行簡單分析。



- 檢索結果頁面左下方 7 處有多個方向的篩選標籤（見下圖），可對檢索結果從適應症、公司、國家/地區、研發階段、靶點/作用機制、技術類型、

研發終止階段/原因、特殊審評、交易、銷售情況等方向按需求進行篩選。  
例如當前圖中顯示的是糖尿病治療相關藥物表格，可點擊技術類型或研發最高階段等進行篩選，獲得更加精煉的結果。

7

▶ Highest Status at Termination

▶ Reason for Discontinuation

▶ Regulatory Designations

▶ Total Reported Sales 2018 (USD M)

▶ Total Foregone Sales (USD M)

▶ Sales and Forecast Data

▶ Drug SWOT

▶ Number of Active Deals

▶ Active Deal Types

▶ Active Companies

▶ Inactive Companies

▶ Indications and Therapy

▶ Company

▶ Status

▶ Country/Territory

▶ Target-based Actions

▶ Other Actions

▶ Technologies

▶ Added Date

▶ Last Change Date

▶ Highest Status

3183 results found for index Search for the search term "diabetes mellitus"

First

Previous

1

2

3

4

5

6

7

8

9

10

Next

Last

Results Per page: 10

Sort by: Relevance

Order Columns

View

1

2

3

4

5

6

7

8

✓ Drug Name

Originator Company

Active Companies

Therapy Area

Active Indications

Target-based Actions

✓ [biased agonists \(diabetes\), Theralin diabetes](#)

Thermal Diabetes LLC

Thermal Diabetes LLC

Endocrine/Metabolic

Diabetes mellitus

✓ [tissue selective therapeutic proteins \(diabetes\), Theralin diabetes](#)

Thermal Diabetes LLC

Thermal Diabetes LLC

Endocrine/Metabolic

Diabetes mellitus

✓ [engineered insulin analogues \(diabetes\), Theralin/Sanofi](#)

Thermal Diabetes LLC

Sanofi SA; Thermal Diabetes LLC

Endocrine/Metabolic

Diabetes mellitus

Insulin ligand; Insulin receptor agonist

✓ [GIPV-301NH2](#)

Steno Diabetes Center

Steno Diabetes Center

Endocrine/Metabolic

Diabetes mellitus

8

- 透過 8 也可打開篩選選項進行對應標籤的再次篩選。
- 我們也非常推薦使用 CLV 功能，針對不同適應症、作用機制、技術類型和研發公司這四個檢索方向快速獲取目標產品全球產品線競爭情報圖表。

## E · 報告頁面

Cortellis 提供多種形式的報告（如藥物報告、專利報告、交易報告、公司報告等），每一種報告都是針對某類內容的綜合性彙總，此處以藥物報告為例，展示報告具體內容：

Drug Name	Originator Company	Active Companies	Therapy Area	Active Indications	Target-based Actions
canagliflozin	Tanabe Seiyaku Co Ltd	Johnson & Johnson; Johnson & Johnson Pharmaceutical Research & Development LLC; Merck & Co Inc; Mitsubishi Tanabe Pharma Corp	Cardiovascular; Endocrine/Metabolic; Genitourinary/Sexual Function; Other/Miscellaneous	Cardiac failure; Diabetic nephropathy; Non-insulin dependent diabetes	Sodium glucose transporter-2 inhibitor

canagliflozin

Snapshot

Highlight Search Terms & Synonyms

Drug Name canagliflozin

Other Drug Names SGLT-2 inhibitors (diabetes/obesity), Tanabe/Johnson & Johnson; SGLT-2 inhibitors (diabetes/obesity), Mitsubishi Tanabe/Johnson & Johnson; SGLT-2 inhibitor (oral, diabetes), Johnson & Johnson; canagliflozin (USAN); TA-7284; JNJ-28431754; canagliflozin; CANA; Invokana; sodium glucose cotransporter-2 inhibitor (oral, diabetes/obesity), Mitsubishi Tanabe/Johnson & Johnson; Canaglu

Originator Company Tanabe Seiyaku Co Ltd

Active Companies Johnson & Johnson Pharmaceutical Research & Development LLC; Vifor Pharma Group; Johnson & Johnson; Merck & Co Inc; Mitsubishi Tanabe Pharma Corp

Therapy Area Cardiovascular; Endocrine/Metabolic; Genitourinary/Sexual Function; Other/Miscellaneous

Inactive Companies Tanabe Seiyaku Co Ltd

Highest Status Launched (Non-insulin dependent diabetes - US - Apr-2013)

Regulatory Designations Fast Track; Paediatric Investigation Plan; Priority Review

Active Indications Diabetic nephropathy; Cardiac failure; Non-insulin dependent diabetes

Inactive Indications Obesity; Insulin dependent diabetes

Target-based Actions Sodium glucose transporter-2 inhibitor

Other Actions Hypoglycemic agent

Technologies Film coating; Small molecule therapeutic; Tablet formulation; Capsule formulation; Oral formulation

Franchises Diabetes, oral SGLT2 inhibitors

EphMRA Codes A6 (ANTI-OBESITY PREPARATIONS, EXCLUDING DIETETICS)

Last Change Date 06-Feb-2020

Added Date 05-Jul-2007

- 點擊檢索結果<sup>1</sup>處的藥物名稱超連接進入藥物報告頁面，同理，點擊專利號、交易名稱、公司名稱的藍色超連接進入專利、交易或公司報告頁面。
- 進入藥物報告頁面後，點擊<sup>2</sup> [Back](#) 可返回至檢索結果列表。
- 點擊<sup>3</sup>處 [Prev](#) 或 [Next](#) 可查看檢索結果列表中位於 [vildagliptin](#) 前一個或後一個藥物的報告。
- 點擊<sup>4</sup>處的 [Alert](#) 或 [Download](#) 設置更新定時提醒或下載藥物報告。
- 藥物報告將與本藥物相關的內容進行彙總，並分類整理，分類標籤如<sup>5</sup>所示，用戶可以按照標籤提示查看相應的概覽、新聞、電話會議逐字稿、券商報告、研發綜述、文獻、研發階段、特殊審評、里程碑事件、化學結構、不同藥物名稱、銷售和預測、臨床試驗、交易和專利、SWOT分析、更新歷史、數據來源等內容。

- 點選 **6** [Search Terms & Synonyms](#) 處可將檢索的關鍵詞重點標示出來，便於用戶查看。
- 7** 為藥物概覽，包括藥物名稱、原研公司、在研/停研公司、研發階段、特殊審評、適應症、靶標、作用機制、技術類型、最新變更時間和記錄添加時間等訊息。點擊公司名稱、特殊審評等超連接可直接獲取相應的詳細內容。

canagliflozin

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Latest Press Releases	DEVELOPMENT PROFILE
Latest Event Transcripts	
Broker Research Reports	Summary
Development Profile	<p>Mitsubishi Tanabe Pharma (following the merger of Mitsubishi Pharma and Tanabe Seiyaku), in collaboration with Johnson &amp; Johnson (J&amp;J), has developed and launched canagliflozin jointly with US licensee Vifor (TA-7284, JNJ-28421754; Invokana; Canaglu), the lead from a series of orally active sodium glucose cotransporter-2 (SGLT-2) inhibitors. The product is indicated in the US as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, with an additional label indication for the reduction in risk of major adverse cardiovascular events (MACE), including heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria [1398387], [2088528]. In the EU, the product is indicated in adults with type 2 diabetes mellitus to improve glycemic control as: monotherapy when diet and exercise alone do not provide adequate glycemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications; and, as add-on therapy with other glucose-lowering products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control [1502241], [2070649]. In Japan, the product is indicated for the treatment of type 2 diabetes mellitus [1574922].</p> <p>In April 2013, the drug was launched in the US for type 2 diabetes [1440862]; in October 2018, the FDA approved the drug for the reduction in risk of MACE, including heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, based on CANVAS trial data [2088528]. In February 2014, canagliflozin was launched in the UK for type 2 diabetes [1624451]. By June 2014, the product had also been launched in Germany [1624623]; however, in September 2014, the product was withdrawn from that market [1624628]. By May 2015, canagliflozin had been launched in the EU [1657870]. In September 2018, the EC approved a label update to include data from the CANVAS program on the reduction in MACE in patients with type 2 diabetes who had either a history of cardiovascular disease or at least two risk factors [2070510]. In September 2014, the drug was launched in Japan for type 2 diabetes [1589579].</p> <p>In September 2019, the FDA approved canagliflozin to reduce the risk of ESKD, doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and chronic kidney disease [2198897]. In July 2019, Janssen submitted an application to the EMA for canagliflozin for the treatment of diabetic nephropathy [2211269]; in August 2019, the EMA accepted the filing for review [2185248]. In December 2016, Japanese approval for diabetic nephropathy was expected in FY2018/2020 [1890869]; in October 2019, launch for diabetic nephropathy in Japan was expected in fiscal 2023 [2215869].</p> <p>The drug is also being developed for the potential treatment of heart failure with either preserved or reduced ejection fraction [2218563]. In November 2019, the CHIEF-HF trial began in heart failure patients with or without type 2 diabetes [2218563].</p>
Literature Review	
Development Status	
Regulatory Designations	
Milestones	

- 點擊 [Development Profile](#) 查看由專業編輯撰寫的藥物研發綜述，該綜述持續更新，同時可以點擊 **8** 處導航快速跳轉至概述、專利和學名藥、註冊、上市前/後、臨床前研究等段落內容。
- 9** 點擊藍色超連接均可查看數據的原始來源。


canagliflozin

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Latest Press Releases	LITERATURE REVIEW
Latest Event Transcripts	Ines Aires & Joaquim Calado, NOVA University of Lisbon and Curry Cabral Hospital, Lisbon, Portugal
Broker Research Reports	Submission date: 09 July 2011 Publication date: 31 October 2011
Development Profile	ABSTRACT
Literature Review	<p>Canagliflozin is an orally active, sodium-glucose cotransporter (SGLT)2 inhibitor, being developed by Mitsubishi Tanabe Pharma in collaboration with Johnson &amp; Johnson for the treatment of type 2 diabetes mellitus (T2DM) and obesity. SGLT2 is the major pathway of glucose re-absorption in the kidney. Its inhibition increases urinary glucose excretion, and therefore SGLT2 has become a therapeutic target for T2DM. In phase I and II clinical trials in patients with T2DM, canagliflozin reduced the renal threshold for glucose excretion, increased urinary glucose excretion, and reduced plasma glucose and HbA1c levels. Data from preclinical studies and phase I/II trials indicate that canagliflozin has a favorable effect on beta-cell function and is associated with significant reductions in body mass. Canagliflozin appears to be safe, even in combination with other commonly used antidiabetic drugs, and most reported side effects are mild in intensity. At the time of publication, data from the extensive, ongoing phase III trial program for canagliflozin in patients with T2DM were awaited.</p> <p>INTRODUCTION</p> <p>Diabetes mellitus (DM) is a metabolic disorder of multiple etiologies characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or a combination of both. According to the International Diabetes Federation, the global incidence of DM in 2010 was ~ 6.6% and it is predicted to increase to ~ 7.8% by 2030 [1048724]. Type 2 (T2) DM is the most prevalent form of this disorder, accounting for &gt; 90% of all cases in the developed world [1206951]. Obesity, defined by a BMI of &gt; 30 kg/m2, is a well recognized risk factor for developing T2DM; nevertheless, most obese and overweight (BMI &gt;= 25 kg/m2) individuals do not develop this condition. It has been stated that individuals with a selective excess of visceral adipose tissue are at a greater risk of insulin resistance (and therefore T2DM), and this probably results from a combination of genetic factors, aberrant fatty acid metabolism and a pro-inflammatory state [1208517], [1208518]. Lifestyle interventions, including caloric restriction and regular exercise leading to losses of &gt; 7% of an individual's body mass, may reduce the incidence of T2DM by up to 58%. This approach is also recommended as the first intervention for patients with newly diagnosed T2DM [1208640]. Even so, most patients eventually require treatment with at least one antidiabetic drug to achieve the target level of glycemic control (HbA1c &lt;= 6.5%) that has been associated with fewer complications of DM [1018664]. However, several clinical trials have recently questioned the benefits of strict glycemic control on either prevention of the micro- and macrovascular complications of DM or overall mortality. In fact, the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was stopped prematurely because of excess mortality in the intensively treated group. These findings were suggested to be related to the side effects of being treated with several antidiabetic drugs, mainly hypoglycemia, body mass gain and fluid retention [1208652].</p>
Development Status	
Regulatory Designations	
Milestones	
Chemical Structures	
Drug Names	
Sales and Forecasts	
Clinical Trials	
Deals and Patents	

- 點擊 [Literature Review](#) 查看文獻綜述 **10**，其是由產業專家或學術界科學家撰寫，將現有文獻彙總分析並在科學或商業利益上對目標藥物進行重點提示。




Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >						
Latest Press Releases	CURRENT DEVELOPMENT STATUS						
Latest Event Transcripts	Companies	Indication	Country/Territory	Status	Date	Source	
Broker Research Reports	Johnson & Johnson Pharmaceutical Research & Development LLC	Non-insulin dependent diabetes	US	Launched	30-Apr-2013	[1444175]	
Development Profile	Johnson & Johnson Pharmaceutical Research & Development LLC	Non-insulin dependent diabetes	UK	Launched	14-Feb-2014	[1624451]	
Literature Review	Johnson & Johnson Pharmaceutical Research & Development LLC	Non-insulin dependent diabetes	EU	Launched	14-Feb-2014	[1624451]	
Development Status	Johnson & Johnson Pharmaceutical Research & Development LLC	Non-insulin dependent diabetes	Mexico	Registered	21-Feb-2014	[1527660]	
Regulatory Designations	Johnson & Johnson	Diabetic nephropathy	Australia	Phase 3 Clinical	21-Feb-2014	[1527660]	
Milestones	Johnson & Johnson Pharmaceutical Research & Development LLC	Non-insulin dependent diabetes	South Korea	Registered	14-Apr-2014	[1660556]	
Chemical Structures	Johnson & Johnson Pharmaceutical Research & Development LLC	Non-insulin dependent diabetes	Canada	Launched	28-May-2014	[2196376]	
Drug Names							
Sales and Forecasts							

- 點擊 **Development Status** 進入研發階段，彙總了藥物當前或歷史研發階段的簡要情況，涵蓋了不同公司針對各適應症所開發藥物的不同研發階段，**11** 處導航欄可快速跳轉至當前或歷史研發階段。
- **12** 每一列內容預設按照日期排序，點擊表頭可以選擇將本列內容按照字母升降排序，點擊  可對相應列表內容進行篩選。
- **13** 點擊藍色超連接可查看對應數據來源，也可以幫助跟蹤停研的原因。

Snapshot  
Latest Press Releases  
Latest Event Transcripts  
Broker Research Reports  
Development Profile  
Literature Review  
Development Status  
Regulatory Designations  
Milestones  
**Chemical Structures**  
Drug Names  
Sales and Forecasts  
Clinical Trials  
Deals and Patents  
SWOT Analysis

CAS Registry Number 842133-18-0 **15**



CONFIDENCE LEVEL **16**



Level 1: Confirmed by Chemical Abstracts Service or the developing company as the correct structure.  
Level 2: Structure identified in Merck index or published by WHO or USAN council.  
Level 3: Structure identified in a peer-reviewed journal.  
Level 4: Structure identified in a non-peer reviewed printed source, such as a meeting handout, press release, or non-company website.  
Level 5: Hand-drawn structure from a conference, or structure based on an informed decision by a Clarivate Analytics patent analyst made by correlating unambiguous chemical information from the company's patent filings with information from other sources such as company publications and communications.

Canagliflozin **14**



Invokana


INN

Trade Name


- **14** 提供化合物結構式，查看結構式時，點擊結構式右上角圖示  得到下拉選項  可以選擇保存 MOL 格式的結構式（以後可直接調用該文件進行結構式檢索）或選擇直接將該結構式轉至結構式檢索框進行檢索、也可選擇將結構式複製至剪貼簿。
- **15** 提供化合物 CAS 註冊號。
- **16** 提供化合物信心度評級，由 level 1 至 level 5 信心度逐級下降，level 1 為經 CAS 或研發公司確認過的化合物結構，level 2 為經 Merck 索引確認或 USAN 委員會公布的化合物結構，level 3 為同行評議的期刊確認的化







- 21 和 24 可以點擊查看與藥物相關的全部交易或專利信息相關列表。
- 22 可以將條形圖切換為專利權人或專利類型兩種不同顯示方式。



- 25 可以查看針對同適應症或類似靶點「戰略藥物」的 SWOT 分析。CCI 中「戰略藥物」指的是：處於臨床 III 期研究以上階段且年銷售額或預測達到 1 億美元以上的藥物。

## F · 藥物研發時程和成功率預測

在檢索得到的藥物列表和單獨是藥物報告頁面，點擊 [Timeline & Success Rates](#) 可以進入藥物研發時程和成功率預測模組。

Search Results

24 results found for index Search for the search term Action Landscape : 'Ret tyrosine kinase receptor inhibitor'

Drug Name	Originator Company	Active Companies	Therapy Area	Active Indications	Target-based Actions
<a href="#">apixafenib hydrochloride</a>	Ambit Biosciences Corp	Ignity Inc	Cancer	Advanced solid tumor; Cancer	Epidermal growth factor receptor antagonist; Raf B protein kinase inhibitor; Ret tyrosine kinase receptor inhibitor
<a href="#">NMS-8666</a>	Nerviano Medical Sciences Srl	Nerviano Medical Sciences Srl	Cancer	Cancer	Ret tyrosine kinase receptor

Drug Report

pralsetinib

Snapshot	Highlight	Search Terms & Synonyms
Latest Press Releases	SNAPSHOT	
Latest Event Transcripts	Drug Name	pralsetinib
Broker Research Reports	Other Drug Names	inhibitor of RET kinase mutations and fusions (NSCLC, thyroid cancer), Blueprint Medicines; BLU-667; BLU-6864; mutant RET kinase inhibitors (cancer), Blueprint Medicines; mutant RET kinase inhibitors (cancer), Blueprint Medicines/CStone Pharmaceuticals; CS-3009; pralsetinib
Development Profile	Originator Company	<a href="#">Blueprint Medicines Corp</a>
Literature Review		

Drug Timeline & Success Rates


1 Company Indication Development Status Country Target Based Action Entity Type Clear all Save 41 Predict

☒ Select all drugs ☐ Select all First to Approval

2 ☐ Predict First to Approval

Company	Indication	Development Status	Region / Country	Date	Regulatory Designation
Forecasted Projects (19)					
<input checked="" type="checkbox"/> Loxo Oncology at Lilly	Fibrosarcoma	Phase 2 Clinical	US	02-Apr-2019	

可以透過 **1** 處對所需預測的臨床試驗進行篩選，**2** 處選擇可以限定為最早上市，點擊 **3** 即可預測。



可以透過 4 處顯示單個項目預測及多個項目賽馬圖形式的預測，5 處點擊模  
 組可以看到更詳細的內容，點擊 6 可以將預測結果保存為圖片或 PPT。

**科睿唯安 台灣客戶服務**

台北市信義區松智路 1 號 11 樓  
ts.support.asia@clarivate.com  
0080-149-1138

[clarivate.com.tw](https://clarivate.com.tw)

[clarivate.com/cortellis](https://clarivate.com/cortellis)